Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

Core Viewpoint - Protalix BioTherapeutics, Inc. will release its financial results for Q2 2024 and provide a business and clinical update on August 14, 2024 [1] Group 1: Financial Results and Updates - The company will host a conference call with investors to discuss financial results and recent corporate and regulatory developments [2] - The conference call is scheduled for August 14, 2024, at 8:30 a.m. EDT [3] Group 2: Conference Call and Webcast Details - Toll-free and international call details are provided for participants [3] - A webcast will be available, and participants are encouraged to access the call 15 minutes early [4] Group 3: Company Overview - Protalix specializes in the development and commercialization of recombinant therapeutic proteins using its ProCellEx plant cell-based expression system [5] - The company has FDA approval for its first product, taliglucerase alfa, for Gaucher disease, and its second product, Elfabrio®, was approved in May 2023 [5] - Protalix has partnered with Chiesi Farmaceutici for the global development of Elfabrio and has a pipeline of therapeutic proteins targeting various diseases [6]